177
Participants
Start Date
May 8, 2012
Primary Completion Date
October 24, 2016
Study Completion Date
October 24, 2016
secukinumab 150 mg
After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
secukinumab 300 mg
After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
placebo
Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
Novartis Investigative Site, Tallinn
Novartis Investigative Site, Martigues
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Charleston
Novartis Investigative Site, Newnan
Novartis Investigative Site, Atlanta
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Mobile
Novartis Investigative Site, Osnabrück
Novartis Investigative Site, Tartu
Novartis Investigative Site, Fridley
Novartis Investigative Site, Skokie
Novartis Investigative Site, Omaha
Novartis Investigative Site, Hot Springs
Novartis Investigative Site, Rouen
Novartis Investigative Site, Houston
Novartis Investigative Site, Bryan
Novartis Investigative Site, Austin
Novartis Investigative Site, Glendale
Novartis Investigative Site, Los Angeles
Novartis Investigative Site, Regensburg
Novartis Investigative Site, Lake Oswego
Novartis Investigative Site, Portland
Novartis Investigative Site, Boston
Novartis Investigative Site, Goodlettsville
Novartis Investigative Site, Hamilton
Novartis Investigative Site, North Bay
Novartis Investigative Site, Waterloo
Novartis Investigative Site, Québec
Novartis Investigative Site, Nice
Novartis Investigative Site, Gera
Novartis Investigative Site, Leipzig
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY